ADAPTED
Alzheimer's disease apolipoprotein pathology for treatment elucidation and development
- Home
- Projects & results
- Project Factsheets
Project Factsheets
Displaying 23 projects/programmes
AETIONOMY
Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy
AMYPAD
Amyloid imaging to prevent Alzheimer’s disease
BD4BO
Big Data for Better Outcomes
EBiSC
European Bank for induced pluripotent Stem Cells
EBiSC2
EBiSC2 – A sustainable European bank for induced pluripotent stem cells
EMIF
European Medical Information Framework
EPAD
European prevention of Alzheimer’s dementia consortium
EQIPD
European Quality In Preclinical Data
IDEA-FAST
Identifying digital endpoints to assess fatigue, sleep and activities in daily living in neurodegenerative disorders and immune-mediated inflammatory diseases
IM2PACT
Investigating mechanisms and models predictive of accessibility of therapeutics (IM2PACT) into the brain
IMPRiND
Inhibiting misfolded protein propagation in neurodegenerative diseases
MOBILISE-D
Connecting digital mobility assessment to clinical outcomes for regulatory and clinical endorsement
MOPEAD
Models of patient engagement for Alzheimer’s disease
NEURONET
Efficiently networking European neurodegeneration research
PD-MIND
Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PD-MitoQUANT
PD-MitoQUANT – A quantitative approach towards the characterisation of mitochondrial dysfunction in Parkinson's disease
PHAGO
Inflammation and AD: modulating microglia function - focussing on TREM2 and CD33
Pharma-Cog
Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development
PRISM
Psychiatric Ratings using Intermediate Stratified Markers: providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD
PRISM 2
Psychiatric ratings using intermediate stratified markers 2
RADAR-AD
Remote assessment of disease and relapse – Alzheimer’s disease
ROADMAP
Real world outcomes across the AD spectrum for better care: multi-modal data access platform
